Business context and reporting period
Entity mismatch: The supplied filing is for Prime Estates & Developments, Inc., not Cosmos Health Inc. It is a Form 10-Q for the quarter ended January 31, 2013, covering the six months then ended; the company’s fiscal year ends July 31. The filing describes Prime Estates as a development-stage company pursuing commercial real estate and related assets. It had not acquired properties or generated operating revenue.
Financial results and liquidity
| Metric | Six months ended Jan. 31, 2013 | Prior-year comparable |
|---|---|---|
| Revenue | $0 | $0 |
| General and administrative expense | $238,762 | $214,579 |
| Net loss | $242,660 | $216,299 |
| Net loss per share | $0.01 | $0.01 |
| Cash used in operating activities | $23,060 | $41,647 |
For the three months ended January 31, 2013, net loss was $114,933 versus $55,914 in the prior-year quarter; G&A was $112,641 versus $54,791. The company reported no revenue, gross profit, or operating margin. No cash interest or income taxes were paid during the six-month period.
At January 31, 2013, cash was $453, total assets $453, and current liabilities $338,986, including $177,500 salaries payable and a $153,739 related-party note payable. Working capital and shareholders’ equity were each in deficit by $338,533. Cash increased by $413 during the six months, principally through $23,473 in related-party advances offset by operating cash use. The filing’s cash-flow statement reports cumulative net cash used in operations since inception of $246,015.
Changes, outlook, and risks
- Six-month G&A increased about 11% and net loss about 12% from the prior-year period; operating cash use narrowed. Quarterly G&A and net loss were each more than twice the prior-year quarter.
- Management attributed higher costs mainly to director share and option compensation, legal expenses, and compliance costs. Related-party interest expense also rose with higher debt.
- Management stated that at least $150,000 was needed for the next 12 months, estimated a monthly burn rate of about $17,000, and separately estimated $220,000 in operating expenses for the coming 12 months. It said additional financing was essential; there was no committed external financing. Directors had indicated an intention to provide advances but were not obligated to do so.
- Management’s plans to acquire properties and raise substantial capital were conditional. It had identified potential Chicago-area properties but had not secured acquisition funding. A hypothetical $10 million raise and proposed property purchases were plans, not commitments or guidance on expected results.
- The company disclosed substantial doubt about its ability to continue as a going concern, citing losses, a working-capital deficit, limited cash, and dependence on new financing. Management said it might be unable to continue if it could not raise funds by the end of May 2013.
- A February 28, 2013 subsequent event reported receipt of $100,000 through a private placement. The GreenEra forest-rights agreement carries stated monthly payments of $5,000 and up to $1.2 million in potential project financing; the company reported $110,000 accrued costs and no cash payments to GreenEra as of January 31.
- Disclosure controls and procedures were reported ineffective. The filing reports no legal proceedings. It also reports issuance of 180,000 shares for director services and grants of 240,000 options at a $0.10 exercise price.
Important facts to verify
- Confirm the filing’s identity and period: it names Prime Estates & Developments, Inc., not Cosmos Health Inc.
- Verify the $100,000 post-period placement, available cash after receipt, and any subsequent funding or property acquisitions.
- Reconcile the filing’s differing funding and expense estimates ($150,000 minimum funding versus $220,000 estimated operating expenses).
- Review related-party advances, salaries payable, and the GreenEra agreement’s payment obligations and accrued costs.
- Check the reported compensation amounts: MD&A cites $120,851 of noncash director compensation, while the cash-flow statement lists $113,351 of stock-based compensation.
- Assess the going-concern risk and ineffective disclosure controls, including whether any remediation or financing commitments followed.